2016-03-11T00:00:00.000-05:00
hormonal treatment,-0.753156
Shareholders,0.332075
Special Meeting,0.452539
current therapies,-0.532425
androgen  receptor,-0.44984
Annual  General,0.452539
CRPC,-0.286144
AR-dependent mechanisms,-0.286144
proprietary therapies,-0.432949
hands,0.449123
Androgen  Deprivation Therapy,-0.60288
primary pathway,-0.435809
clinical-stage pharmaceutical company,-0.432949
tumor progression,-0.753156
male cancer death,-0.697913
prostate cancer growth,-0.435809
stock option plan,0.449123
Company  LLP,0.21161
prostate cancer,-0.562944
commonly diagnosed cancer,-0.697913
functional NTD,0.809606
testosterone,-0.685107
British Columbia,0.211136
disease progression,-0.551621
castrate levels,-0.685107
common cause,-0.697913
Chartered Professional Accountants,0.217293
lethal variant,-0.685107
castration-resistant prostate cancer,-0.559028
metastatic castration-resistant prostate,-0.685107
